TAK 285

Known as: EGFR/HER2 Kinase Inhibitor TAK-285, TAK-285, TAK285 
An orally bioavailable, small molecule and dual kinase inhibitor of human epidermal growth factor receptors 1 (EGFR/ErbB1) and 2 (HER2/ErbB2), with… (More)

Topic mentions per year

Topic mentions per year

2011-2018
02420112018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
The gatekeeper T798M mutation in HER2 kinase domain has been observed to considerably shift drug sensitivity to HER2 in breast… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2014
2014
The human epidermal growth factor receptor (HER) family plays a major role in cancer cell proliferation. Overexpression of these… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Introduction This phase 1 study assessed safety, maximum tolerated dose (MTD), pharmacokinetics, cerebrospinal fluid (CSF… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2013
2013
Breast cancer therapy has improved following the development of drugs with specific molecular targets, exemplified by inhibitors… (More)
  • figure 1
  • figure 3
  • table 1
  • figure 4
  • figure 5
Is this relevant?
2013
2013
The epidermal growth factor receptor (EGFR) family plays a critical role in vital cellular processes and in various cancers… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Background:This phase I first-in-human study was conducted in Japanese patients to investigate the safety, pharmacokinetics (PKs… (More)
  • table 2
  • table 1
  • table 3
  • table 4
  • figure 1
Is this relevant?
2012
2012
TAK-285, an investigational, orally active HER2/EGRF inhibitor is in clinical development for potential use in HER2 over… (More)
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
Aberrant signaling of ErbB family members human epidermal growth factor 2 (HER2) and epidermal growth factor receptor (EGFR) is… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 4
Is this relevant?
2011
2011
2538 Background: TAK-285 is an investigational, orally active, dual HER2/EGFR inhibitor with antitumor activity in mouse… (More)
Is this relevant?
2011
2011
Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been… (More)
Is this relevant?